检索结果 - Manmath Patekar

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (<scp>SCULPTURE</scp> Extension Study)

    Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (<scp>SCULPTURE</scp> Ex... 由 Robert Bissonnette, Thomas A. Luger, Diamant Thaçi, D. Toth, A. Lacombe, S. Xia, Rafał Mazur, Manmath Patekar, Pascal Charef, M. Milutinovic, C. Leonardi, Ulrich Mrowietz

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

    Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a doubl... 由 Jerry Bagel, Andrew Blauvelt, John K Nia, Peter W. Hashim, Manmath Patekar, Ana de Vera, Kashif Ahmad, Bertrand Paguet, S. Xia, Elisa Muscianisi, Mark Lebwohl

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

    Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind rand... 由 Christine Bodemer, Andrzej Kaszuba, Külli Kingo, Athanasios Tsianakas, Akimichi Morita, Enrique Rivas, P. Papanastasiou, Deborah Keefe, Manmath Patekar, Pascal Charef, L. Zhang, Susan Cafoncelli, C. Papavassilis

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*

    Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized contro... 由 Matthias Augustin, Kristian Reich, Paul S. Yamauchi, Andreas Pinter, Jerry Bagel, Swapnil Dahale, R. You, Gerard Bruin, Jimena Djimopoulos, Bertrand Paguet, Pascal Charef, Manmath Patekar, Deborah Keefe

    出版 2022
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: Results from the Phase-3 Pivotal Trials

    Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: Results from the Phase-3 Pivotal Trials 由 Luís Felipe Ensina, Jonathan A. Bernstein, Gordon Sussman, Marcus Maurer, Ana M. Giménez‐Arnau, Sarabjit Saini, Vineeth Varanasi, Avantika Barve, Eva Hua, Manmath Patekar, Thomas Severin

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

    Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results) 由 Jerry Bagel, John K Nia, Peter W. Hashim, Manmath Patekar, Ana de Vera, Sophie Hugot, Kuan Sheng, Summer Xia, I. Gilloteau, Elisa Muscianisi, Andrew Blauvelt, Mark Lebwohl

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis

    Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis 由 Boni E. Elewski, John W. Baddley, Atul Deodhar, Marina Magrey, Phoebe Rich, Enrique R. Soriano, Jennifer Soung, Weibin Bao, Dorothy L. Keininger, Kwaku Marfo, Manmath Patekar, Abhishek Sharma, Abhijit Shete, Mark Lebwohl

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial 由 Iain B. McInnes, Philip J. Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T. Ritchlin, Proton Rahman, Désirée van der Heijde, R. Landewé, Philip G. Conaghan, Alice B. Gottlieb, Hanno B. Richards, Luminita Pricop, Gregory Ligozio, Manmath Patekar, Shephard Mpofu

    出版 2015
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis

    Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis 由 Lin Cai, Jianzhong Zhang, Xu Yao, Jun Gu, Quanzhong Liu, Min Zheng, Shifa Zhang, Jinhua Xu, Cheng‐Xin Li, Hao Cheng, Qing Guo, Weili Pan, Shenqiu Li, Ruoyu Li, Zaipei Guo, Zhiqi Song, Shanshan Li, Xiuqin Dong, Linda Wang, Rong Fu, P. Regnault, Pascal Charef, Rafał Mazur, Manmath Patekar

    出版 2020
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: